Difference between revisions of "November 2026"

From Seth's Wiki
Jump to navigation Jump to search
 
(14 intermediate revisions by the same user not shown)
Line 29: Line 29:
  
 
===November 11===
 
===November 11===
−
* Outline submission guidelines for IJOA (15 minutes)
+
* Outlined submission guidelines for IJOA
−
* Flu shot (15 minutes)
+
* Met w/ Derek and Kai. Jonah is in the process of getting hired and can work 8-10 hrs per week. Will need IRB approval only for data that I want to publish.
−
* Demo Respiration.AI hardware (1 hr)
+
* Toured Lara Brewer's lab. Met Elizabeth, Ali, and her graduating PhD student. Respiration.AI hardware, O2 delivery device, Hgb mass loss.
−
* Ketamine systematic review (2.5 hr)
+
** Get IRB approval to NOT use the Neptune.
−
* SCD-PV systematic review, IRB stuff (1 hr)
+
** Analyze PACU and volunteer dataset (ataxic breathing, whatever else).
−
* Lab website (1 hr)
+
* [[SCD Fluid Bolus]] systematic review, e-mailed Emma about IRB stuff
−
* Read CLASS-D papers (1 hr)
+
* Ketamine systematic review. Little bit depressing.
−
* Open and briefly explore CLASS-D data (1 hr) -> 8 hrs total
+
 
 +
===November 20===
 +
* Ketamine and postpartum/postoperative depression. Explore systematic reviews, assess quality of evidence, relevance, identify areas for future research.
 +
* Lab website
 +
* Read CLASS-D papers
 +
* Open and briefly explore CLASS-D data
 +
 
 +
==Ketamine Review==
 +
===Postoperative Depression===
 +
Ovid MEDLINE(R) ALL <1946 to November 10, 2026>
 +
 
 +
# (HAM-D or Hamilton Depression Rating Scale or HDRS or Hamilton Rating Scale for Depression or Beck Depression Inventory or BDI or PHQ-9 or HADS-D or HADS or "Hospital Anxiety and Depression Scale" or Zung Self-Rating Depression Scale or Zung Self Rating Depression Scale or Self Rating Depression Scale or Self-Rating Depression Scale).mp. or Depressive Disorder/ or Mood Disorders/ or Major Depressive Disorder/ or Depression/ (n=340793)
 +
# Perioperative Period/ or Operating Rooms/ or General Surgery/ or Postoperative Complications/ or (postoperative or post operative or post-operative or operating room or intraoperative or intra operative or intra-operative).mp. (n=1392167)
 +
# Ketamine/ or esketamine.mp. (n=18740)
 +
# 1 and 2 and 3 (n=107)
 +
 
 +
'''Summary: 14 of these were review articles. Between 2022 and now, 9 systematic reviews were done w/wo meta analysis, most of them showing a beneficial and sustained effect of ketamine with minimal side effects aside from dizziness and dissociation.'''
 +
 
 +
{| class="wikitable"
 +
|+ Caption text
 +
|-
 +
! Year !! First Author !! Journal !! Study Type !! Population !! Intervention !! Comparator !! Outcome
 +
|-
 +
| 2026 || He<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:7qS3F--yeFIJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDP47s:AIL1Nv4AAAAAavTJ-7tyFiEi1Qu_9yh4Y6UEgLo&scisig=AIL1Nv4AAAAAavTJ-8Gwfmjrk5PwQo5j_k1Xif8&scisf=4&ct=citation&cd=-1&hl=en</ref> || J of Investigative Surgery || double-blind RCT || 132 adult patients undergoing lap radical resection for CRC || Intraoperative bolus at induction of 0.5 mg/kg ketamine plus an infusion of 1 mg/kg added to PCIA post-op || Placebo || Improved HADS-D on POD 1 and 3.
 +
|-
 +
| 2026 || Chen<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:Z0jyPF9LhrQJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDMjfQ:AIL1Nv4AAAAAavTKlfQFArkJyVW4ef74Zs6FvOw&scisig=AIL1Nv4AAAAAavTKld7Rnl9NytXrtPhhYZwCiZo&scisf=4&ct=citation&cd=-1&hl=en</ref> || Annals of Medicine || double-blind RCT || 84 adult patients getting acoustic neuroma surgery || 0.2 mg/kg/hr continuous infusion of ketamine followed by 1 mg/kg PCIA post-op.  || placebo || Esketamine significantly reduced the incidence of depression (HADS-D >7) at POD1 (7.7% versus 31.6%; relative risk 0.24, 95% CI: 0.08-0.80, p = 0.008) and POD3 (0.0% versus 15.8%, relative risk 0.00, 95% CI: 0.00-0.47, p = 0.031)
 +
|-
 +
| 2026 || Liu<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:3s6CSOQL3SMJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDNCVA:AIL1Nv4AAAAAavTLEVDx8d26l8RmdQYOZ4DQjDs&scisig=AIL1Nv4AAAAAavTLEesuSPiaLgBcLmj2qnd2d1A&scisf=4&ct=citation&cd=-1&hl=en</ref> || BMC Psychiatry || double-blind RCT || 120 adult patients scheduled for breast cancer surgery || 0.2 mg/kg at induction, followed by a continuous infusion of 0.1 mg/kg/hr || placebo || At POD30, the ketamine group achieved a significantly greater reduction in PHQ-9 scores compared to the control group, with an adjusted mean difference of 0.96 points (95% CI 0.42-1.51, P < 0.01)
 +
|-
 +
| 2026 || Tan<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:z9BP0cZwPRsJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDNmfo:AIL1Nv4AAAAAavTLgfrycb2mADviVzu-EWrvFeo&scisig=AIL1Nv4AAAAAavTLgdl5KWI3gXgLYzOqVDeedSw&scisf=4&ct=citation&cd=-1&hl=en</ref> || BMC Anesthesiology || RCT || 53 adult patients with PD || 0.25 mg/kg ketamine at induction followed by 0.125 mg/kg/hr continuous infusion || placebo || SDS scores at POD 1, 3, and 7 were lower in the ketamine group.
 +
|-
 +
| 2025 || He<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:vBqsVnBf8b0J:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDN5mk:AIL1Nv4AAAAAavTL_mmlQrmOOlg5-9TZ5DE_CoM&scisig=AIL1Nv4AAAAAavTL_nMF6lRqFz3eARfm9LHiYYQ&scisf=4&ct=citation&cd=-1&hl=en</ref> || Psycho-Oncology || RCT || 230 adult patients with mild-to-moderate depressive symptoms undergoing abdominal tumor resection || 0.4 mg/kg ketamine at induction || placebo || On POD1 the ketamine group had a slightly higher treatment response (OR 1.4), and a mean decrease in PHQ-9 of 1, but it was not sustained at day 3 or 7.
 +
|-
 +
| 2025 || Zhang<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:zMc0lUuZvr8J:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDKcyo:AIL1Nv4AAAAAavTMaypzfaFPiqjGh6Ilu5BmmIs&scisig=AIL1Nv4AAAAAavTMa-ZfpuJUpbWVrKvrh2teIc4&scisf=4&ct=citation&cd=-1&hl=en</ref> || Pharmacological Research || multi-center, double-blind RCT || 132 cardiac valve surgery patients || 0.3 mg/kg single dose ketamine at induction || placebo || HADS scores were significantly lower at POD7 in the ketamine group with rates of depression of 7% vs 31% in placebo.
 +
|-
 +
| 2025 || Luo<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:ojpnDyfjUGMJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDIWd4:AIL1Nv4AAAAAavTOQd7afHEnxuJ-ehyTePuUWGo&scisig=AIL1Nv4AAAAAavTOQSLKahBZX979AB-jvMWeDkk&scisf=4&ct=citation&cd=-1&hl=en</ref> || Actas Espanolas de Psiquiatria || RCT || 280 patients who underwent elective caesarean section under spinal anaesthesia || single intravenous injection of esketamine at a dose of 0.25 mg/kg (diluted to 5 mL and administered intravenously within 10 min after foetus removal) || placebo || Primary outcome was EPDS score on PPD3. The patients with an extroverted-stable personality in the esketamine group had a lower PPD incidence than those in the control group (11.90% vs. 25.70%, p < 0.05). No statistical difference in overall PPD incidence was observed between the two groups (35.7% vs. 29.3%, p > 0.05), suggesting a possible treatment modifying effect of personality type.
 +
|-
 +
| 2025 || Wang<ref>https://scholar.googleusercontent.com/scholar.bib?q=info:FOb98jzqXU0J:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDX1M8:AIL1Nv4AAAAAavTRzM85cuA_p5XiofsUNAEsSQs&scisig=AIL1Nv4AAAAAavTRzL74T6uGJ2c_GQAEgLMI5jY&scisf=4&ct=citation&cd=-1&hl=en</ref> || BMC Geriatrics || double-blind RCT || 200 patients undergoing laparoscopic abdominal surgery aged 60 years or older || 0.3 mg/kg/h starting 10 min before the induction of anesthesia and continuing until the end of the surgical procedure || placebo || HADS-D score was significantly lower on POD1 and 3 (visually estimated from figure to be 10 vs. 11 and 7 vs 8 respectively).
 +
|-
 +
| Example || Example || Example || Example || Example || Example || Example || Example
 +
|-
 +
| Example || Example || Example || Example || Example || Example || Example || Example
 +
|-
 +
| Example || Example || Example || Example || Example || Example || Example || Example
 +
|-
 +
| Example || Example || Example || Example || Example || Example || Example || Example
 +
|}
 +
 
 +
===Postpartum Depression===
 +
Ovid MEDLINE(R) ALL <1946 to November 10, 2026>
 +
 
 +
# (HAM-D or Hamilton Depression Rating Scale or HDRS or Hamilton Rating Scale for Depression or EPDS or Edinburgh Postnatal Depression Scale or Beck Depression Inventory or BDI or PHQ-9 or HADS-D or HADS or "Hospital Anxiety and Depression Scale" or Zung Self-Rating Depression Scale or Zung Self Rating Depression Scale or Self Rating Depression Scale or Self-Rating Depression Scale or Baby Blues).mp. or Depressive Disorder/ or Mood Disorders/ or Major Depressive Disorder/ or Depression/ or Depression, Postpartum/ (n=349125)
 +
# Ketamine/ or esketamine.mp. (n=18740)
 +
# (Caesarean Section or Caesarean Delivery or Cesarean Section or Cesarean Delivery or Parturient).mp. or Pregnancy/ or Cesarean Section/ or Anesthesia, Obstetrical/ or Delivery, Obstetric/ or Obstetric Labor Complications/ or Postpartum Period/ (n=1113875)
 +
# 1 and 2 and 3 (n=78)
 +
# limit 4 to "review articles" (n=7)
 +
 
 +
'''Summary: there are 7 review articles, with the earliest dating to 2022. 5 were systematic reviews and meta analyses. All favored ketamine for the reduction of PPD, but low-quality of evidence and medication side effects were frequently mentioned.'''

Latest revision as of 22:40, 11 November 2026

Lab Vision We explore mechanisms whereby anesthetics lead to amnesia, hypnosis (i.e. impaired behavioral responsiveness), immobility, and analgesia. We develop pharmacologic and device-based methods to modulate components of anesthesia non-invasively.

AY '26-'27 Goals → November Goals

  • Submit a manuscript for publication
    • Methohexital data sharing agreement or IRB
    • Ketamine systematic review with Grace/Brian
  • Submit RISE 1 application
    • Read CLASS-D papers from Christian
    • Start mining the CLASS-D dataset
    • Talk to Emma about process of getting IRB approval for a study
  • Identify additional funding sources and apply
  • Start recruiting a research team
    • Lab website
    • Update faculty profile
    • Timeline for matching MD/PhD students

Weekly Summaries

November 5

  • Took the day off.
  • Teasing out the appropriate interpretation of behavioral screening assays for C. elegans. How do you differentiate if a drug effect is analgesic, paralytic, sedative/hypnotic, or amnestic?
    • Can they be paralyzed with rocuronium? Would it be fatal?
    • Do worms sleep? When? How long? How do you know? What are several ways you might wake them up?
    • What are some learning/memory assays in worms that don't require movement?
    • Paralyze the worms and then see if you can teach them something (e.g. to associate a sound or light with an aversive stimulus)
    • Repeat the experiment with propofol, which we know decreases locomotion.

November 11

  • Outlined submission guidelines for IJOA
  • Met w/ Derek and Kai. Jonah is in the process of getting hired and can work 8-10 hrs per week. Will need IRB approval only for data that I want to publish.
  • Toured Lara Brewer's lab. Met Elizabeth, Ali, and her graduating PhD student. Respiration.AI hardware, O2 delivery device, Hgb mass loss.
    • Get IRB approval to NOT use the Neptune.
    • Analyze PACU and volunteer dataset (ataxic breathing, whatever else).
  • SCD Fluid Bolus systematic review, e-mailed Emma about IRB stuff
  • Ketamine systematic review. Little bit depressing.

November 20

  • Ketamine and postpartum/postoperative depression. Explore systematic reviews, assess quality of evidence, relevance, identify areas for future research.
  • Lab website
  • Read CLASS-D papers
  • Open and briefly explore CLASS-D data

Ketamine Review

Postoperative Depression

Ovid MEDLINE(R) ALL <1946 to November 10, 2026>

  1. (HAM-D or Hamilton Depression Rating Scale or HDRS or Hamilton Rating Scale for Depression or Beck Depression Inventory or BDI or PHQ-9 or HADS-D or HADS or "Hospital Anxiety and Depression Scale" or Zung Self-Rating Depression Scale or Zung Self Rating Depression Scale or Self Rating Depression Scale or Self-Rating Depression Scale).mp. or Depressive Disorder/ or Mood Disorders/ or Major Depressive Disorder/ or Depression/ (n=340793)
  2. Perioperative Period/ or Operating Rooms/ or General Surgery/ or Postoperative Complications/ or (postoperative or post operative or post-operative or operating room or intraoperative or intra operative or intra-operative).mp. (n=1392167)
  3. Ketamine/ or esketamine.mp. (n=18740)
  4. 1 and 2 and 3 (n=107)

Summary: 14 of these were review articles. Between 2022 and now, 9 systematic reviews were done w/wo meta analysis, most of them showing a beneficial and sustained effect of ketamine with minimal side effects aside from dizziness and dissociation.

Caption text
Year First Author Journal Study Type Population Intervention Comparator Outcome
2026 He[1] J of Investigative Surgery double-blind RCT 132 adult patients undergoing lap radical resection for CRC Intraoperative bolus at induction of 0.5 mg/kg ketamine plus an infusion of 1 mg/kg added to PCIA post-op Placebo Improved HADS-D on POD 1 and 3.
2026 Chen[2] Annals of Medicine double-blind RCT 84 adult patients getting acoustic neuroma surgery 0.2 mg/kg/hr continuous infusion of ketamine followed by 1 mg/kg PCIA post-op. placebo Esketamine significantly reduced the incidence of depression (HADS-D >7) at POD1 (7.7% versus 31.6%; relative risk 0.24, 95% CI: 0.08-0.80, p = 0.008) and POD3 (0.0% versus 15.8%, relative risk 0.00, 95% CI: 0.00-0.47, p = 0.031)
2026 Liu[3] BMC Psychiatry double-blind RCT 120 adult patients scheduled for breast cancer surgery 0.2 mg/kg at induction, followed by a continuous infusion of 0.1 mg/kg/hr placebo At POD30, the ketamine group achieved a significantly greater reduction in PHQ-9 scores compared to the control group, with an adjusted mean difference of 0.96 points (95% CI 0.42-1.51, P < 0.01)
2026 Tan[4] BMC Anesthesiology RCT 53 adult patients with PD 0.25 mg/kg ketamine at induction followed by 0.125 mg/kg/hr continuous infusion placebo SDS scores at POD 1, 3, and 7 were lower in the ketamine group.
2025 He[5] Psycho-Oncology RCT 230 adult patients with mild-to-moderate depressive symptoms undergoing abdominal tumor resection 0.4 mg/kg ketamine at induction placebo On POD1 the ketamine group had a slightly higher treatment response (OR 1.4), and a mean decrease in PHQ-9 of 1, but it was not sustained at day 3 or 7.
2025 Zhang[6] Pharmacological Research multi-center, double-blind RCT 132 cardiac valve surgery patients 0.3 mg/kg single dose ketamine at induction placebo HADS scores were significantly lower at POD7 in the ketamine group with rates of depression of 7% vs 31% in placebo.
2025 Luo[7] Actas Espanolas de Psiquiatria RCT 280 patients who underwent elective caesarean section under spinal anaesthesia single intravenous injection of esketamine at a dose of 0.25 mg/kg (diluted to 5 mL and administered intravenously within 10 min after foetus removal) placebo Primary outcome was EPDS score on PPD3. The patients with an extroverted-stable personality in the esketamine group had a lower PPD incidence than those in the control group (11.90% vs. 25.70%, p < 0.05). No statistical difference in overall PPD incidence was observed between the two groups (35.7% vs. 29.3%, p > 0.05), suggesting a possible treatment modifying effect of personality type.
2025 Wang[8] BMC Geriatrics double-blind RCT 200 patients undergoing laparoscopic abdominal surgery aged 60 years or older 0.3 mg/kg/h starting 10 min before the induction of anesthesia and continuing until the end of the surgical procedure placebo HADS-D score was significantly lower on POD1 and 3 (visually estimated from figure to be 10 vs. 11 and 7 vs 8 respectively).
Example Example Example Example Example Example Example Example
Example Example Example Example Example Example Example Example
Example Example Example Example Example Example Example Example
Example Example Example Example Example Example Example Example

Postpartum Depression

Ovid MEDLINE(R) ALL <1946 to November 10, 2026>

  1. (HAM-D or Hamilton Depression Rating Scale or HDRS or Hamilton Rating Scale for Depression or EPDS or Edinburgh Postnatal Depression Scale or Beck Depression Inventory or BDI or PHQ-9 or HADS-D or HADS or "Hospital Anxiety and Depression Scale" or Zung Self-Rating Depression Scale or Zung Self Rating Depression Scale or Self Rating Depression Scale or Self-Rating Depression Scale or Baby Blues).mp. or Depressive Disorder/ or Mood Disorders/ or Major Depressive Disorder/ or Depression/ or Depression, Postpartum/ (n=349125)
  2. Ketamine/ or esketamine.mp. (n=18740)
  3. (Caesarean Section or Caesarean Delivery or Cesarean Section or Cesarean Delivery or Parturient).mp. or Pregnancy/ or Cesarean Section/ or Anesthesia, Obstetrical/ or Delivery, Obstetric/ or Obstetric Labor Complications/ or Postpartum Period/ (n=1113875)
  4. 1 and 2 and 3 (n=78)
  5. limit 4 to "review articles" (n=7)

Summary: there are 7 review articles, with the earliest dating to 2022. 5 were systematic reviews and meta analyses. All favored ketamine for the reduction of PPD, but low-quality of evidence and medication side effects were frequently mentioned.

  1. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:7qS3F--yeFIJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDP47s:AIL1Nv4AAAAAavTJ-7tyFiEi1Qu_9yh4Y6UEgLo&scisig=AIL1Nv4AAAAAavTJ-8Gwfmjrk5PwQo5j_k1Xif8&scisf=4&ct=citation&cd=-1&hl=en
  2. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:Z0jyPF9LhrQJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDMjfQ:AIL1Nv4AAAAAavTKlfQFArkJyVW4ef74Zs6FvOw&scisig=AIL1Nv4AAAAAavTKld7Rnl9NytXrtPhhYZwCiZo&scisf=4&ct=citation&cd=-1&hl=en
  3. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:3s6CSOQL3SMJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDNCVA:AIL1Nv4AAAAAavTLEVDx8d26l8RmdQYOZ4DQjDs&scisig=AIL1Nv4AAAAAavTLEesuSPiaLgBcLmj2qnd2d1A&scisf=4&ct=citation&cd=-1&hl=en
  4. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:z9BP0cZwPRsJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDNmfo:AIL1Nv4AAAAAavTLgfrycb2mADviVzu-EWrvFeo&scisig=AIL1Nv4AAAAAavTLgdl5KWI3gXgLYzOqVDeedSw&scisf=4&ct=citation&cd=-1&hl=en
  5. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:vBqsVnBf8b0J:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDN5mk:AIL1Nv4AAAAAavTL_mmlQrmOOlg5-9TZ5DE_CoM&scisig=AIL1Nv4AAAAAavTL_nMF6lRqFz3eARfm9LHiYYQ&scisf=4&ct=citation&cd=-1&hl=en
  6. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:zMc0lUuZvr8J:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDKcyo:AIL1Nv4AAAAAavTMaypzfaFPiqjGh6Ilu5BmmIs&scisig=AIL1Nv4AAAAAavTMa-ZfpuJUpbWVrKvrh2teIc4&scisf=4&ct=citation&cd=-1&hl=en
  7. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:ojpnDyfjUGMJ:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDIWd4:AIL1Nv4AAAAAavTOQd7afHEnxuJ-ehyTePuUWGo&scisig=AIL1Nv4AAAAAavTOQSLKahBZX979AB-jvMWeDkk&scisf=4&ct=citation&cd=-1&hl=en
  8. ↑ https://scholar.googleusercontent.com/scholar.bib?q=info:FOb98jzqXU0J:scholar.google.com/&output=citation&scisdr=CoZuVH0GEIjgiyDX1M8:AIL1Nv4AAAAAavTRzM85cuA_p5XiofsUNAEsSQs&scisig=AIL1Nv4AAAAAavTRzL74T6uGJ2c_GQAEgLMI5jY&scisf=4&ct=citation&cd=-1&hl=en
Retrieved from "http://www.sethvogel.com/wiki/index.php?title=November_2026&oldid=1417"